Previous reports have demonstrated that the administration of PAD4 inhibitors like GSK484 at the same dose of our study (4 mg/kg) but delivered daily for one week suppressed NETosis in mice with cancer-associated kidney injury [52]. This evidence concerns the gene PADI4 and kidney injury.